Bcl-2 inhibitor combo for advanced HR+ breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new Bcl-2 inhibitor (BGB-21447) combined with other therapies for advanced HR+/HER2- breast cancer that has already been treated with hormone therapy and a CDK4/6 inhibitor. It aims to see if these combinations are safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be HR-positive and HER2-negative (a common type).
- You must have had at least one prior treatment for advanced cancer, including hormone therapy and a CDK4/6 inhibitor.
- You must not have taken a Bcl-2 inhibitor before.
- You must have no uncontrolled or untreated cancer spread to the brain or spinal cord lining.
- You must be able to get around and take care of yourself (ECOG status 0 or 1).
- If you are a woman who can still have children, you must use effective birth control during the study and for a period after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called BGB-43395 alone or with other treatments for advanced solid tumors, especially breast cancer. The goal is to find the best dose and see how well it works. It may be an option if your cancer has not responded to other treatments.
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
This trial tests a combination of three drugs (lenvatinib, pembrolizumab, and fulvestrant) for people with a certain type of advanced breast cancer that has stopped responding to previous hormone therapy. The goal is to see if this new combination can help shrink or control the cancer.
This trial tests whether combining three medicines can better control hormone-receptor–positive, HER2-negative metastatic breast cancer that cannot be cured with surgery or radiation. It may help shrink tumors and slow disease growth compared with standard hormone therapy approaches.
This trial tests a new drug, HRS-6209, combined with other treatments for people with hormone receptor-positive, HER2-negative cancer. The goal is to see if the combination is safe and works well.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Hear when a new Hormone-receptor-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.